Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

New scheme of innovation funding in the Netherlands

Promising care must find its way to patients more quickly through inclusion in the basic health insurance. That is why the Dutch Ministry of Health, Welfare and Sport has adjusted the promising care with the new subsidy scheme. Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) carries out the scheme in collaboration with the Dutch Organization for Health Research and Development (Nederlandse organisatie voor gezondheidsonderzoek en zorginnovatie, ZonMw). The scheme will replace existing procedure with conditional reimbursement of medical technologies.

With this regulation, the Ministry of Health, Welfare and Sport makes a maximum of €69 million available annually. Medical devices and specific groups of medicines (ATMPs and off-label medications that have had a market registration for seven years) are eligible for this regulation. A project subsidy is granted for a maximum of 6 years. After the research project has ended, an assessment of the Dutch Healthcare Institute within six months will carry out the evaluation for inclusion in the basic health insurance. There will be a possibility for submission of the subsidy scheme twice a year. The procedure consists of a project synopsis and a detailed application.

The scheme will be officially open in March 2019. Applications will be received until mid-May 2019.

The scheme will replace existing scheme of conditional reimbursement of technology with not sufficient evidence.

See full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.